Goelzer Investment Management Inc. grew its stake in Shire PLC (NASDAQ:SHPG) by 7.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,151 shares of the biopharmaceutical company’s stock after purchasing an additional 1,617 shares during the period. Goelzer Investment Management Inc.’s holdings in Shire PLC were worth $3,698,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. grew its holdings in Shire PLC by 4,217.7% during the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock worth $249,755,000 after acquiring an additional 1,400,275 shares during the period. Janus Henderson Group PLC grew its holdings in Shire PLC by 22,560.3% during the second quarter. Janus Henderson Group PLC now owns 1,286,881 shares of the biopharmaceutical company’s stock worth $212,683,000 after acquiring an additional 1,281,202 shares during the period. Glenview Capital Management LLC grew its holdings in Shire PLC by 69.7% during the second quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock worth $284,756,000 after acquiring an additional 707,500 shares during the period. Northern Trust Corp grew its holdings in Shire PLC by 45.5% during the second quarter. Northern Trust Corp now owns 1,307,339 shares of the biopharmaceutical company’s stock worth $216,064,000 after acquiring an additional 408,843 shares during the period. Finally, OZ Management LP acquired a new position in Shire PLC during the second quarter worth $57,614,000. 19.27% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This piece was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.com-unik.info/2017/11/03/goelzer-investment-management-inc-buys-1617-shares-of-shire-plc-shpg.html.
Shire PLC (NASDAQ:SHPG) last issued its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.64 by $0.17. The business had revenue of $3.70 billion for the quarter. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. The business’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.17 earnings per share.
The business also recently announced a semiannual dividend, which was paid on Friday, October 20th. Investors of record on Friday, September 8th were issued a $0.1527 dividend. This represents a dividend yield of 0.21%. The ex-dividend date was Thursday, September 7th. Shire PLC’s payout ratio is 17.23%.
SHPG has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Shire PLC from a “hold” rating to a “sell” rating in a report on Monday, July 17th. ValuEngine lowered Shire PLC from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $222.00 price objective on shares of Shire PLC in a report on Thursday, September 14th. Stifel Nicolaus reaffirmed a “buy” rating and set a $245.00 price objective on shares of Shire PLC in a report on Sunday, October 8th. Finally, BTIG Research reaffirmed a “buy” rating and set a $242.00 price objective on shares of Shire PLC in a report on Monday, July 17th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $211.00.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
What are top analysts saying about Shire PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire PLC and related companies.